C16020 trial (ixazomib): what clinicians have said so far
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
- NCT02046070 ↗
- Completed
- Millennium Pharmaceuticals, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on C16020 (ixazomib plus cyclophosphamide plus dexamethasone in newly diagnosed or relapsed/refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on C16020 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Cyclophosphamide; Ixazomib; Dexamethasone
- Arms
- Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM) · Experimental
- Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM) · Experimental
- Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM) · Experimental
- Enrollment
- 148
- Primary outcomes
- Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants
- Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Start
- Mar 5, 2014
- Primary completion
- Jun 29, 2018
- Results posted
- Yes
- Registry record
- NCT02046070 · updated Jul 17, 2019
Publications
linked from the registry- Dimopoulos MA, Grosicki S, Jedrzejczak WW, Nahi H, Gruber A, Hansson M, Gupta N, Byrne C, Labotka R, Teng Z, Yang H, Grzasko N, Kumar S. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer. 2019 Jan;106:89-98. doi: 10.1016/j.ejca.2018.09.011. Epub 2018 Nov 22. PubMed 30471652
- Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol. 2019 Feb;184(4):536-546. doi: 10.1111/bjh.15679. Epub 2018 Nov 20. PubMed 30460684